Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALGS Stock Forecast 2025-2026
$11.33
Current Price
$69.72M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ALGS Price Targets
+1,444.6%
To High Target of $175.00
+385.4%
To Median Target of $55.00
+217.7%
To Low Target of $36.00
ALGS Price Momentum
+12.3%
1 Week Change
+69.6%
1 Month Change
-67.2%
1 Year Change
-71.6%
Year-to-Date Change
-75.8%
From 52W High of $46.80
+201.3%
From 52W Low of $3.76
📊 TOP ANALYST CALLS
Did ALGS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aligos is one of their latest high-conviction picks.
Latest ALGS Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ALGS has a bullish consensus with a median price target of $55.00 (ranging from $36.00 to $175.00). The overall analyst rating is N/A (N/A/10). Currently trading at $11.33, the median forecast implies a 385.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALGS Analyst Ratings
4
Buy
0
Hold
0
Sell
ALGS Price Target Range
Low
$36.00
Average
$55.00
High
$175.00
Current: $11.33
Latest ALGS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALGS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 12, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $50.00 |
| Aug 18, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Assumes | $50.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $70.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $70.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $75.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Initiates | $75.00 |
| Jan 17, 2023 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $7.00 |
| Jan 6, 2023 | Piper Sandler | Yasmeen Rahimi | Overweight | Upgrade | $3.00 |
| Jan 6, 2023 | Jefferies | Michael Yee | Buy | Upgrade | $3.00 |
| Nov 3, 2022 | SVB Leerink | Roanna Ruiz | Market Perform | Maintains | $2.00 |
| May 5, 2022 | SVB Leerink | Roanna Ruiz | Market Perform | Downgrade | $3.00 |
| Mar 23, 2022 | Piper Sandler | Yasmeen Rahimi | Neutral | Downgrade | $4.00 |
| Mar 23, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $7.00 |
| Mar 11, 2022 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $15.00 |
| Mar 11, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $11.00 |
| Feb 16, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $10.00 |
| Jan 7, 2022 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $15.00 |
| Jan 7, 2022 | JP Morgan | Eric Joseph | Neutral | Downgrade | $12.00 |
Aligos Therapeutics Inc. (ALGS) Competitors
The following stocks are similar to Aligos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ALGS
Aligos Therapeutics
mkt cap
61.47M
Aligos Therapeutics Inc. (ALGS) Financial Data
Aligos Therapeutics Inc. has a market capitalization of $69.72M with a P/E ratio of -0.5x. The company generates $2.65M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -41.6% quarter-over-quarter, while maintaining an operating margin of -3,827.4% and return on equity of -141.8%.
Valuation Metrics
Market Cap
$69.72M
Enterprise Value
$-31,556,716
P/E Ratio
-0.5x
PEG Ratio
0.6x
Price/Sales
25.1x
Growth & Margins
Revenue Growth (YoY)
-41.6%
Gross Margin
N/A
Operating Margin
-3,827.4%
Net Margin
0.0%
EPS Growth
-41.6%
Financial Health
Cash/Price Ratio
+142.1%
Current Ratio
4.7x
Debt/Equity
8.4x
ROE
-141.8%
ROA
-54.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aligos Therapeutics Inc. (ALGS) Business Model
About Aligos Therapeutics Inc.
What They Do
Develops targeted antiviral and liver disease therapies.
Business Model
Aligos Therapeutics Inc. operates as a clinical-stage biotechnology company focused on developing innovative therapies for chronic liver and viral diseases. The company generates revenue through research collaborations and licensing agreements, allowing it to fund its drug development pipeline while addressing significant unmet medical needs in the healthcare sector.
Additional Information
The company's pipeline includes promising drug candidates like Pevifoscorvir sodium for chronic hepatitis B and ALG-055009 for metabolic dysfunction-associated steatohepatitis. Aligos Therapeutics leverages its expertise in hepatology and virology to create best-in-class molecules aimed at improving patient outcomes in serious health conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
68
CEO
Dr. Lawrence M. Blatt MBA, Ph.D.
Country
United States
IPO Year
2020
Website
www.aligos.comAligos Therapeutics Inc. (ALGS) Latest News & Analysis
Latest News
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript
20 days ago
Quick Summary
Aligos Therapeutics, Inc. (ALGS) will participate in the Jefferies London Healthcare Conference on November 17, 2025, at 10:00 AM EST, featuring CEO Lawrence Blatt.
Why It Matters
Aligos Therapeutics' participation in the Jefferies London Healthcare Conference can signal potential investor interest and market insights, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Aligos Therapeutics granted 23,600 non-qualified stock options to new employees on November 11, 2025, as part of their compensation package.
Why It Matters
The stock options granted to new employees signal company growth and investment in talent, potentially boosting future performance and investor confidence in Aligos Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aligos Therapeutics (Nasdaq: ALGS) reported positive data from eight presentations at the AASLD's The Liver Meeting 2025, focusing on liver and viral disease therapies.
Why It Matters
Positive data from Aligos Therapeutics at a major conference boosts investor confidence in its drug development, potentially increasing stock value and attracting interest in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
1 month ago
Quick Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS) reported its third-quarter 2025 financial results and business progress, focusing on therapies for liver and viral diseases.
Why It Matters
Aligos Therapeutics' Q3 2025 report indicates progress in clinical trials and financial health, affecting stock performance and investor confidence in its future growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS) will present at two upcoming investor conferences, focusing on therapies for liver and viral diseases.
Why It Matters
Aligos Therapeutics' management presentation at investor conferences may signal confidence in their pipeline, potentially boosting investor interest and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aligos Therapeutics (Nasdaq: ALGS) will report its Q3 2025 financial results on November 6, 2025, before U.S. market opens.
Why It Matters
Aligos Therapeutics' upcoming Q3 2025 financial results may impact stock performance, influencing investor sentiment based on revenue, expenses, and clinical progress.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ALGS Stock
What is Aligos Therapeutics Inc.'s (ALGS) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Aligos Therapeutics Inc. (ALGS) has a median price target of $55.00. The highest price target is $175.00 and the lowest is $36.00.
Is ALGS stock a good investment in 2026?
According to current analyst ratings, ALGS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALGS stock?
Wall Street analysts predict ALGS stock could reach $55.00 in the next 12 months. This represents a 385.4% increase from the current price of $11.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aligos Therapeutics Inc.'s business model?
Aligos Therapeutics Inc. operates as a clinical-stage biotechnology company focused on developing innovative therapies for chronic liver and viral diseases. The company generates revenue through research collaborations and licensing agreements, allowing it to fund its drug development pipeline while addressing significant unmet medical needs in the healthcare sector.
What is the highest forecasted price for ALGS Aligos Therapeutics Inc.?
The highest price target for ALGS is $175.00 from at , which represents a 1,444.6% increase from the current price of $11.33.
What is the lowest forecasted price for ALGS Aligos Therapeutics Inc.?
The lowest price target for ALGS is $36.00 from at , which represents a 217.7% increase from the current price of $11.33.
What is the overall ALGS consensus from analysts for Aligos Therapeutics Inc.?
The overall analyst consensus for ALGS is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $55.00.
How accurate are ALGS stock price projections?
Stock price projections, including those for Aligos Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 6:11 AM UTC